Tabersonine Enhances Olaparib Sensitivity through FHL1-Mediated Epithelial-Mesenchymal Transition in an Ovarian Tumor

Area of Science:

• Oncology
• Pharmacology
• Molecular Biology

Background:

• Ovarian cancer (OVC) is a highly aggressive gynecological malignancy with limited treatment options.
• Olaparib shows efficacy in OVC, but resistance necessitates improved therapeutic strategies.
• Investigating novel agents to enhance olaparib's effectiveness is crucial for better patient outcomes.

Purpose of the Study:

• To identify natural compounds that can resensitize OVC to olaparib treatment.
• To elucidate the molecular mechanisms underlying the synergistic effects of combined olaparib and tabersonine therapy.
• To evaluate the therapeutic potential of tabersonine in combination with olaparib for OVC treatment.

Main Methods:

• Cell proliferation assays and xenograft models were used to assess the combined efficacy of olaparib and tabersonine.
• Quantitative proteomics was employed to identify molecular targets and pathways involved in tabersonine's action.
• Expression levels of key proteins, including E-cadherin, N-cadherin, vimentin, and FHL1, were analyzed.

Main Results:

• Combined olaparib and tabersonine treatment synergistically inhibited OVC cell proliferation and suppressed tumor growth in vivo.
• The combination therapy effectively suppressed epithelial-mesenchymal transition (EMT) and induced DNA damage responses.
• Tabersonine upregulated FHL1 expression, which was identified as a key mediator in suppressing EMT and enhancing olaparib sensitivity.

Conclusions:

• Tabersonine enhances olaparib chemosensitivity in ovarian cancer by targeting FHL1-mediated EMT.
• The combined therapy demonstrates significant potential for inhibiting OVC progression and metastasis.
• Tabersonine represents a promising therapeutic agent for improving olaparib-based treatment strategies in ovarian cancer.